187 related articles for article (PubMed ID: 27131282)
1. Docking, QM/MM, and molecular dynamics simulations of the hexose transporter from Plasmodium falciparum (PfHT).
Fonseca AL; Nunes RR; Braga VM; Comar M; Alves RJ; Varotti Fde P; Taranto AG
J Mol Graph Model; 2016 May; 66():174-86. PubMed ID: 27131282
[TBL] [Abstract][Full Text] [Related]
2. Why is the Plasmodium falciparum hexose transporter a promising new drug target?
Joët T; Morin C; Fischbarg J; Louw AI; Eckstein-Ludwig U; Woodrow C; Krishna S
Expert Opin Ther Targets; 2003 Oct; 7(5):593-602. PubMed ID: 14498822
[TBL] [Abstract][Full Text] [Related]
3. Interaction of O-(undec-10-en)-yl-D-glucose derivatives with the Plasmodium falciparum hexose transporter (PfHT).
Ionita M; Krishna S; Léo PM; Morin C; Patel AP
Bioorg Med Chem Lett; 2007 Sep; 17(17):4934-7. PubMed ID: 17587575
[TBL] [Abstract][Full Text] [Related]
4. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target.
Joet T; Eckstein-Ludwig U; Morin C; Krishna S
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7476-9. PubMed ID: 12792024
[TBL] [Abstract][Full Text] [Related]
5. Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds.
Ortiz D; Guiguemde WA; Johnson A; Elya C; Anderson J; Clark J; Connelly M; Yang L; Min J; Sato Y; Guy RK; Landfear SM
PLoS One; 2015; 10(4):e0123598. PubMed ID: 25894322
[TBL] [Abstract][Full Text] [Related]
6. Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering.
Heitmeier MR; Hresko RC; Edwards RL; Prinsen MJ; Ilagan MXG; Odom John AR; Hruz PW
PLoS One; 2019; 14(5):e0216457. PubMed ID: 31071153
[TBL] [Abstract][Full Text] [Related]
7. The hexose transporter of Plasmodium falciparum is a worthy drug target.
Joët T; Krishna S
Acta Trop; 2004 Feb; 89(3):371-4. PubMed ID: 14744563
[TBL] [Abstract][Full Text] [Related]
8. New antimalarial targets: the example of glucose transport.
Patel AP; Staines HM; Krishna S
Travel Med Infect Dis; 2008; 6(1-2):58-66. PubMed ID: 18342277
[TBL] [Abstract][Full Text] [Related]
9. Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality.
Slavic K; Straschil U; Reininger L; Doerig C; Morin C; Tewari R; Krishna S
Mol Microbiol; 2010 Mar; 75(6):1402-13. PubMed ID: 20132450
[TBL] [Abstract][Full Text] [Related]
10. Probing structure/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives.
Fayolle M; Ionita M; Krishna S; Morin C; Patel AP
Bioorg Med Chem Lett; 2006 Mar; 16(5):1267-71. PubMed ID: 16361099
[TBL] [Abstract][Full Text] [Related]
11. A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.
Kraft TE; Heitmeier MR; Putanko M; Edwards RL; Ilagan MX; Payne MA; Autry JM; Thomas DD; Odom AR; Hruz PW
Antimicrob Agents Chemother; 2016 Dec; 60(12):7407-7414. PubMed ID: 27736766
[TBL] [Abstract][Full Text] [Related]
12. An
Altharawi A; Riadi Y; Tahir Ul Qamar M
J Biomol Struct Dyn; 2023; 41(23):14450-14459. PubMed ID: 36812293
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Plasmodium vivax hexose transporters and effects of a parasitocidal inhibitor.
Joët T; Chotivanich K; Silamut K; Patel AP; Morin C; Krishna S
Biochem J; 2004 Aug; 381(Pt 3):905-9. PubMed ID: 15107012
[TBL] [Abstract][Full Text] [Related]
14. Identification of new promising Plasmodium falciparum superoxide dismutase allosteric inhibitors through hierarchical pharmacophore-based virtual screening and molecular dynamics.
Araujo JSC; de Souza BC; Costa Junior DB; Oliveira LM; Santana IB; Duarte AA; Lacerda PS; Dos Santos Junior MC; Leite FHA
J Mol Model; 2018 Jul; 24(8):220. PubMed ID: 30056475
[TBL] [Abstract][Full Text] [Related]
15. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.
Kraft TE; Armstrong C; Heitmeier MR; Odom AR; Hruz PW
Antimicrob Agents Chemother; 2015 Oct; 59(10):6203-9. PubMed ID: 26248369
[TBL] [Abstract][Full Text] [Related]
16. Homology modeling and molecular dynamics simulation of N-myristoyltransferase from Plasmodium falciparum: an insight into novel antimalarial drug design.
Paul P; Chowdhury A; Das Talukdar A; Choudhury MD
J Mol Model; 2015 Mar; 21(3):37. PubMed ID: 25663521
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the interaction of antimalarial agents with Plasmodium falciparum glutathione reductase through molecular mechanical calculations.
Ferreira FHDC; Pinto LR; Oliveira BA; Daniel LV; Navarro M; Delgado GYS
J Mol Model; 2024 May; 30(6):181. PubMed ID: 38780838
[TBL] [Abstract][Full Text] [Related]
19. Studies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysis.
Tjhin ET; Staines HM; van Schalkwyk DA; Krishna S; Saliba KJ
FEBS Lett; 2013 Oct; 587(19):3182-7. PubMed ID: 23954294
[TBL] [Abstract][Full Text] [Related]
20. Computational identification of Plasmodium falciparum RNA pseudouridylate synthase as a viable drug target, its physicochemical properties, 3D structure prediction and prediction of potential inhibitors.
Afolabi R; Chinedu S; Ajamma Y; Adam Y; Koenig R; Adebiyi E
Infect Genet Evol; 2022 Jan; 97():105194. PubMed ID: 34968763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
